International General Insurance Holdings Ltd.

IGIC
About the company

International General Insurance Holdings Ltd. engages in the provision of specialty insurance and reinsurance solutions in the United Kingdom, Europe, Central and South America, the Middle East and Africa. The company operates through three segments: Specialty Long-tail, Specialty Short-tail, and Reinsurance.

Country: JordanPrice: $24.36Market Cap: $1.0B

Investment snapshot

31%positive consensus
Scored 1d ago

Positive

5

BUY / PASS

Neutral / negative

7 / 4

NEUTRAL / FAIL

Median fair value

$36.78

+51.0% vs price

Models with upside

8 / 16

Positive margin of safety

Strongest signal

Models split on IGIC at $24.36 — fair values range $17.79–$74.87

Key risk

Split decision: 7 NEUTRAL · 4 FAIL · 3 PASS · 2 BUY

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictBUYFAILFAILPASSBUYPASSNEUTRALFAILNEUTRALNEUTRALNEUTRALNEUTRALNEUTRALPASSFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/A
Margin of Safety+25.8%+67.5%+66.3%N/A+42.1%+23.4%+24.7%+40.2%-14.1%+54.2%-36.9%N/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2025

Latest source filing: 2026-04-21

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-04-21

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-04-21

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-04-21

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-11-01

Latest source filing: 2026-04-21

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-04-21

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-04-21

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-04-21

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-04-21

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-11-01

Latest source filing: 2026-04-21

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-04-21

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-04-21

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-04-21

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-04-21

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-04-21

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-04-21

Score computed: 2026-11-14

Where It Passes

  • Valuation models80% pass✓ 8✗ 2▾

    Models split on IGIC at $24.36 — fair values range $17.79–$74.87

    Graham fair value$32.83
    ✓Graham+25.8% margin vs $24.36
    Buffett fair value$74.87
    ✓Buffett+67.5% margin vs $24.36
    Lynch fair value$72.25
    ✓Lynch+66.3% margin vs $24.36
    Dreman fair value$42.10
    ✓Dreman+42.1% margin vs $24.36
    Munger fair value$31.80
    ✓Munger+23.4% margin vs $24.36
    Pabrai fair value$32.36
    ✓Pabrai+24.7% margin vs $24.36
    Akre fair value$40.72
    ✓Akre+40.2% margin vs $24.36
    Marks fair value$21.35
    ✗Marks-14.1% margin vs $24.36
    Ackman fair value$53.15
    ✓Ackman+54.2% margin vs $24.36
    Templeton fair value$17.79
    ✗Templeton-36.9% margin vs $24.36
  • Growth75% pass✓ 10✗ 2▾

    6 of 8 pass — Sleep and Neff object

    EPS Growth (3-yr avg, 10-yr window)2340.6%
    ✓Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)0.09
    ✓Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR96.0%
    ✓Lynch15-30% (Fast Grower); > 0% to pass
    EPS Growth Direction$0.05 (2017) -> $2.89 (2025)
    ✓DremanPositive over recent years
    EPS CAGR66.1% CAGR over 8 years
    ✓Dreman> 5% annualized
    Positive Net Income Frequency9/9 years positive
    ✓MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth8.0%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency4/5 years with positive EPS growth
    ✓AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR96.0% CAGR over 5 years
    ✓Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trend
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR261.1%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR96.0% over 5 years
    ✗Neff7%-20% annualized
  • Valuation67% pass✓ 18✗ 8▾

    8 of 12 pass — Dreman, Asness, Schloss +1 more object

    Price / Book Value per Share1.5x
    ✗Dreman< 1.2x✓Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Price / 3-yr avg EPS8.7x
    ✓Graham<= 15x
    Price-to-Book Ratio1.5x
    ✓Graham<= 1.5x
    P/E x P/B12.80
    ✓Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)0.09
    ✓Lynch< 1.0 (ideally < 0.5)
    Price / EPS8.4x
    ✓Dreman< 12x✓Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)9.7x
    ✗Dreman< 8x
    Valuation ReasonablenessP/E=8.4x, OE Yield=12.4%
    ✓MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldP/E=8.4x, FCF Yield=10.4%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/E=8.4x, P/B=1.5x
    ✓MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic Value42.1% (IV=$42.10 vs Price=$24.36)
    ✓Marks>= 20% below intrinsic value
    Price / FCF per Share9.7x
    ✓Ackman<= 25
    Price vs. Trailing Low114% of trailing low ($21.30)
    ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization+12.33%; #483/6340 (top 7.6%)
    ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.6888; #2241/6449 (top 34.7%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS8.4x
    ✓NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E11.91
    ✓Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share1.47x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change+124.8%
    ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.5013; #2622/5247 (top 50.0%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization+10.40%; #712/4519 (top 15.8%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date-3.37%; #3034/6202 (top 48.9%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Cash Flow60% pass✓ 8✗ 4▾

    6 of 10 pass — Lynch, Piotroski, Dreman +1 more object

    Free Cash Flow Proxy$129.8M
    ✓BuffettPositive and growing
    FCF Positive and Growing$107.2M
    ✗LynchPositive and growing
    Operating Cash Flow$108.1M
    ✓PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=5.15%, ROA=6.05%
    ✗PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)9.7x
    ✗Dreman< 8x
    P/E or FCF YieldP/E=8.4x, FCF Yield=10.4%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive8/9 years FCF positive
    ✓MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap10.3%
    ✓Ackman>= 4%
    Price / FCF per Share9.7x
    ✓Ackman<= 25
    Positive Operating Cash Flow frequency8/9 years positive
    ✓SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$107.2M
    ✓Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization+10.40%; #712/4519 (top 15.8%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Verdicts56% pass✓ 5✗ 4▾

    Split decision: 7 NEUTRAL · 4 FAIL · 3 PASS · 2 BUY

    Overall verdict
    ✓GrahamBUY (5/7)✗BuffettFAIL (2/7)✗LynchFAIL (3/6)✓PiotroskiPASS (F-Score 4)✓DremanBUY (7/10)✓MungerPASS (2/4)•PabraiNEUTRAL (2/3)✗AkreFAIL (2/6)•MarksNEUTRAL (4/5)•AckmanNEUTRAL (6/9)•TempletonNEUTRAL (6/8)•SleepNEUTRAL (4/6)•AsnessNEUTRAL (Not ranked)✓NeffPASS (5/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked)

Where It Falls Short

  • Efficiency0% pass✗ 5▾

    All 4 investors flag IGIC's efficiency

    Revenue / Total Assets Change YoY0.26x -> 0.25x
    ✗PiotroskiImproved YoY
    Return on Invested Capital
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/2 years above 12% (latest -58.3%)
    ✗SleepROIC > 12% in a majority of years
  • Debt & Leverage9% pass✓ 1✗ 12▾

    10 of 11 flag IGIC's debt & leverage — Buffett, Lynch, Dreman +7 more

    Debt/Equity & Interest Coverage
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity
    ✗Lynch< 0.33
    Cash - Long-term Debt
    ✗LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Total Debt / Shareholders' Equity
    ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
    Debt Levels
    ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDA
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity
    ✗Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)
    ✗AsnessTop 30% of eligible cross-section
    Current Assets / Current Liabilities
    ✗SchlossCurrent ratio >= 1.50x (app cutoff)
  • Profitability47% pass✓ 20✗ 12▾

    8 of 15 flag IGIC's profitability — Graham, Buffett, Piotroski +5 more

    Positive EPS (10 years)9/10 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)2340.6%
    ✓Graham>= 33% growth
    Net Income Positive (10+ years)9/10 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)18.9%
    ✓Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy$129.8M
    ✓BuffettPositive and growing
    Earnings Variance (10-yr CoV)0.92
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)0.09
    ✓Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR96.0%
    ✓Lynch15-30% (Fast Grower); > 0% to pass
    ROE17.9%
    ✓Lynch> 15%
    Net Income / Total Assets6.05%
    ✓PiotroskiROA > 0
    ROA Change YoY6.63% -> 6.05% (delta: -0.58%)
    ✗PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=5.15%, ROA=6.05%
    ✗PiotroskiCFO/Assets > ROA
    Pre-Tax Income / Revenue24.6%
    ✓Dreman>= 8%
    Net Income / Shareholders' Equity17.9%
    ✓Dreman> 12%
    Margin of SafetyP/E=8.4x, P/B=1.5x
    ✓PabraiP/B < 1.5 or P/E < 15
    Return on Equity20.1% (3-yr avg)
    ✓AkreROE > 20% (3-year avg)
    Discount to Intrinsic Value42.1% (IV=$42.10 vs Price=$24.36)
    ✓Marks>= 20% below intrinsic value
    Positive Net Income Frequency9/9 years positive
    ✓MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue
    ✗Ackman>= 15%
    Net Income / Shareholders Equity17.9%
    ✓Ackman>= 15%
    5-Year EPS CAGR96.0% CAGR over 5 years
    ✓Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend
    ✗TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trend
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization+12.33%; #483/6340 (top 7.6%)
    ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity+17.90%; #927/5226 (top 17.7%)
    ✓AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.0123; #972/5884 (top 16.5%)
    ✓AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR96.0% over 5 years
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years9/9 years positive
    ✓Schloss>= 70% positive over 5-10 observed years (app rule)

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Insurance
SIC Sector: Insurance Carriers
Size: Small Cap($1.0B)
Revenue: $516.9M-4.1% YoY
Net Income: $127.2M-5.9% YoY

Financial Snapshot

Operating Margin--
Return on Equity17.9%
Debt / Equity--
Current Ratio--
EPS (Diluted)$2.89−3.0% 1y
Buybacks (1y)$61.9M
Buybacks (2y)$85.1M
Shares Retired4.9% / 7.0% 2y
Sector-adjusted criteria: Insurer

Insurers file unclassified balance sheets with no inventory or current accounts, so those criteria are omitted rather than failed for missing data. Return-on-invested-capital tests are omitted too: float funds the balance sheet but never appears in invested capital, and the portfolio it is invested in would be subtracted as spare cash. Debt tests are kept — an insurer’s borrowings are real leverage on top of underwriting.

Shareholder Return

Fiscal 2025

Retired 4.9% of shares last year, 7.0% over two.

Buybacks
$61.9M
Dividends
$46.2M

What drove EPS

A buyback raises earnings per share without the company earning more. This splits each year's change into the two.

FY22
87.8% = 90.6% + −1.5%
FY23
38.6% = 32.5% + 4.6%
FY24
16.9% = 14.3% + 2.2%
FY25
−3.0% = −5.9% + 3.1%
Earnings Fewer shares More shares

The two parts do not sum exactly to the total — the difference is the cross-term, plus preferred capital where the company has any. It is left visible rather than distributed into the other two.

Share count is the denominator the filer used for diluted EPS, recovered as net income ÷ EPS — not the balance-sheet count, which is a point-in-time figure and would put the timing difference into this split. Years with a loss are omitted: a smaller share count makes a loss per share larger, so the decomposition inverts.

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

MetricFY 2025
Sources
  • 20-F · 2026-04-21
FY 2024
Sources
  • 20-F · 2025-04-01
FY 2023
Sources
  • 20-F · 2024-04-08
FY 2022
Sources
  • 20-F · 2024-04-08
FY 2021
Sources
  • 20-F · 2024-04-08
Market Cap$1.0Bcurrent$996.3Mest.$524.8Mest.$314.4Mest.$309.1Mest.
Revenue$516.9M↓4%$539.0M↑8%$499.2M↑27%$393.2M↑12%$350.4M
Operating Income-----$345.9M↓13%-$305.7M↓1%-$301.7M
Net Income$127.2M↓6%$135.2M↑14%$118.2M↑32%$89.2M↑91%$46.8M
EPS (Diluted)$2.89↓3%$2.98↑17%$2.55↑39%$1.84↑88%$0.98
Gross Margin———21.7%↑74%12.5%
Operating Margin——-69.3%↑11%-77.7%↑10%-86.1%
ROE17.9%↓13%20.6%↓6%21.9%↑1%21.7%↑77%12.3%
Total Debt------$3.1M↓18%$3.8M
Shareholders' Equity$710.1M↑8%$654.8M↑21%$540.4M↑32%$410.9M↑8%$381.1M
Current Ratio—————
Debt / Equity———0.01↓24%0.01
Operating Cash Flow$108.1M↓48%$209.5M↑7%$196.6M↑27%$154.9M↓12%$175.3M
Free Cash Flow$107.2M↓47%$202.8M↑5%$193.4M↑26%$153.6M↓11%$172.9M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Insurance

IGIC vs Peers — Financial Grading

Revenue$516.9MBottom 25%
Net Income$127.2MBottom 25%
ROE17.9%Median
D/E—
Op. Margin—
Curr. Ratio—
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchPiotroskiDreman
UNITEDHEALTH GROUP INCUNH$365.1B$407.46$447.6B$12.1B12.0%0.784.2%0.793/74/72/6F-Score 63/10
PROGRESSIVE CORP/OH/PGR$136.6B$235.78$87.7B$11.3B37.3%0.23——2/72/74/6F-Score 68/10
MARSH & MCLENNAN COMPANIES, INC.MRSH$98.8B$207.78$27.0B$4.2B27.2%1.2823.1%1.103/73/72/6F-Score 65/10
CHINA LIFE INSURANCE CO LTDCILJF$85.1B$3.01——————5/71/73/6F-Score 55/10
Aon plcAON$71.8B$338.31$17.2B$3.7B39.5%1.6325.3%1.112/74/73/6F-Score 63/10
HUMANA INCHUM$54.0B$450.00$129.7B$1.2B6.7%0.702.1%2.003/72/71/6F-Score 44/10
SUN LIFE FINANCIAL INCSLF$40.5B$72.93$30.6B$2.6B14.5%0.33——3/73/72/6F-Score 66/10
HARTFORD INSURANCE GROUP, INC.HIG$36.8B$137.48$28.4B$3.8B20.2%0.23——3/73/74/6F-Score 78/10